Compare HOUR & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOUR | NSRX |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | Israel |
| Employees | 151 | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 53.5M |
| IPO Year | 2021 | N/A |
| Metric | HOUR | NSRX |
|---|---|---|
| Price | $1.90 | $4.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | ★ 10.9K | 2.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.57 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $138,252,861.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.14 | ★ N/A |
| Revenue Growth | ★ 4.64 | N/A |
| 52 Week Low | $1.10 | $3.99 |
| 52 Week High | $6.84 | $9.99 |
| Indicator | HOUR | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 38.65 |
| Support Level | $1.74 | $3.99 |
| Resistance Level | $1.95 | $6.39 |
| Average True Range (ATR) | 0.04 | 0.46 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 8.33 | 32.81 |
Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.